Cadrenal Therapeutics, Common Stock Price on November 26, 2024
| CVKD Stock | 15.19 1.04 7.35% |
If you're considering investing in Cadrenal Stock, it is important to understand the factors that can impact its price. As of today, the current price of Cadrenal Therapeutics, stands at 15.19, as last reported on the 1st of December, with the highest price reaching 15.38 and the lowest price hitting 14.03 during the day. Cadrenal Therapeutics, is relatively risky given 3 months investment horizon. Cadrenal Therapeutics, secures Sharpe Ratio (or Efficiency) of 0.16, which signifies that the company had a 0.16% return per unit of standard deviation over the last 3 months. We were able to collect data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.34% are justified by taking the suggested risk. Use Cadrenal Therapeutics, mean deviation of 6.06, and Risk Adjusted Performance of 0.1428 to evaluate company specific risk that cannot be diversified away.
At present, Cadrenal Therapeutics,'s Common Stock Shares Outstanding is projected to increase significantly based on the last few years of reporting. . At present, Cadrenal Therapeutics,'s Price To Book Ratio is projected to slightly grow based on the last few years of reporting. The current year's Price Fair Value is expected to grow to 1.32, whereas Price Earnings To Growth Ratio is forecasted to decline to (0.1). Cadrenal Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Cadrenal |
Sharpe Ratio = 0.1617
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CVKD | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.29 actual daily | 73 73% of assets are less volatile |
Expected Return
| 1.34 actual daily | 26 74% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Cadrenal Therapeutics, is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cadrenal Therapeutics, by adding it to a well-diversified portfolio.
Price Book 7.384 | Book Value 3.091 | Enterprise Value 20.8 M | Enterprise Value Ebitda 0.2128 | Shares Float 687.3 K |
Cadrenal Therapeutics, Main Headline on 26th of November 2024
Filed transaction by Cadrenal Therapeutics, Common Officer Chief Operating Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Cadrenal Therapeutics, Valuation on November 26, 2024
It is possible to determine the worth of Cadrenal Therapeutics, on a given historical date. On November 26, 2024 Cadrenal was worth 13.55 at the beginning of the trading date compared to the closed value of 13.71. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Cadrenal Therapeutics, stock. Still, in general, we apply an absolute valuation method to find Cadrenal Therapeutics,'s value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cadrenal Therapeutics, where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Cadrenal Therapeutics,'s related companies.
| Open | High | Low | Close | Volume | |
| 15.28 | 15.30 | 13.13 | 13.56 | 63,133 | |
11/26/2024 | 13.55 | 13.99 | 13.55 | 13.71 | 33,422 |
| 14.43 | 14.43 | 13.19 | 14.15 | 33,026 |
| Backtest Cadrenal Therapeutics, | | | Cadrenal Therapeutics, History | | | Cadrenal Therapeutics, Valuation | Previous | Next |
Cadrenal Therapeutics, Trading Date Momentum on November 26, 2024
| On November 27 2024 Cadrenal Therapeutics, Common was traded for 14.15 at the closing time. The top price for the day was 14.43 and the lowest listed price was 13.19 . The trading volume for the day was 33 K. The trading history from November 27, 2024 was a factor to the next trading day price growth. The overall trading delta against the next closing price was 3.21% . The overall trading delta against the current closing price is 5.76% . |
Cadrenal Therapeutics, Fundamentals Correlations and Trends
By evaluating Cadrenal Therapeutics,'s financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Cadrenal Therapeutics,'s main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Cadrenal financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Cadrenal Therapeutics, Stock history
Cadrenal Therapeutics, investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Cadrenal is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Cadrenal Therapeutics, will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Cadrenal Therapeutics, stock prices may prove useful in developing a viable investing in Cadrenal Therapeutics,
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 868.2 K | 904.1 K | |
| Net Loss | -6.6 M | -6.9 M |
Cadrenal Therapeutics, Stock Technical Analysis
Cadrenal Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Cadrenal Therapeutics, Period Price Range
Low | December 1, 2024
| High |
0.00 | 0.00 |
Cadrenal Therapeutics, Common cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Cadrenal Therapeutics, December 1, 2024 Market Strength
Market strength indicators help investors to evaluate how Cadrenal Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cadrenal Therapeutics, shares will generate the highest return on investment. By undertsting and applying Cadrenal Therapeutics, stock market strength indicators, traders can identify Cadrenal Therapeutics, Common entry and exit signals to maximize returns
Cadrenal Therapeutics, Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Cadrenal Therapeutics,'s price direction in advance. Along with the technical and fundamental analysis of Cadrenal Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Cadrenal to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1428 | |||
| Jensen Alpha | 1.16 | |||
| Total Risk Alpha | 0.0556 | |||
| Sortino Ratio | 0.1844 | |||
| Treynor Ratio | 0.699 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Cadrenal Stock analysis
When running Cadrenal Therapeutics,'s price analysis, check to measure Cadrenal Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cadrenal Therapeutics, is operating at the current time. Most of Cadrenal Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Cadrenal Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cadrenal Therapeutics,'s price. Additionally, you may evaluate how the addition of Cadrenal Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |